Nitroglycerin drives endothelial nitric oxide synthase activation via the phosphatidylinositol 3-kinase/protein kinase B pathway

Nitroglycerin (GIN) has been clinically used to treat angina pectoris and acute heart episodes for over 100 years. The effects of GTN have long been recognized and active research has contributed to the unraveling of numerous metabolic routes capable of converting GIN to the potent vasoactive messenger nitric oxide. Recently, the mechanism by which minute doses of GIN elicit robust pharmacological responses was revisited and eNOS activation was implicated as an important route mediating vasodilation induced by low GTN doses (1-50 nM). Here, we demonstrate that at such concentrations the pharmacologic effects of nitroglycerin are largely dependent on the phosphatidylinositol 3-kinase, Akt/PKB, and phosphatase and tensin homolog deleted on chromosome 10 (PTEN) signal transduction axis. Furthermore, we demonstrate that nitroglycerin-dependent accumulation of 3,4,5-InsP(3), probably because of inhibition of PTEN, is important for eNOS activation, conferring a mechanistic basis for GIN pharmacological action at pharmacologically relevant doses. (C) 2011 Elsevier Inc. All rights reserved.

National Institute of Environmental Health Sciences Division of Intramural Research, an American Heart Association [09SDG2250933]

National Institute of Environmental Health Sciences Division of Intramural Research, an American Heart Association

National Heart Lung and Blood [R01 HL070187]

National Heart Lung and Blood

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo

Conselho Nacional de Pesquisa de Desenvolvimento Cientifico e Tecnologico

Conselho Nacional de Pesquisa de Desenvolvimento Cientifico e Tecnologico